2-1250 Waverley Street
Winnipeg, MB R3T 6C6
Canada
204 487 7412
https://www.medicure.com
Sektor(en): Healthcare
Branche: Drug Manufacturers - Specialty & Generic
Vollzeitmitarbeiter:
Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
---|---|---|---|---|
Dr. Albert David Friesen Ph.D. | Founder, CEO & Chairman of the board | 232,2k | N/A | 1947 |
Dr. Neil Owens Ph.D. | President & COO | 220,38k | N/A | N/A |
Mr. Haaris Uddin B.Com., CPA | Chief Financial Officer | 128,19k | N/A | N/A |
Dr. Reuben Saba Ph.D. | Vice President of Scientific & Medical Affairs | 151k | N/A | N/A |
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing Sodium Nitroprusside injection, and Generic ANDA 2 and 3 for acute cardiology; and TARDOCAL, to treat neurological indications. It offers products through retail and mail order pharmacies. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.
Medicure Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.